Amarin

AMRN · NASDAQ

$11.48−$0.05 (−0.43%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $11.53

About AMRN

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The firm operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Employees: 80
Headquarters: DUBLIN
Listed: Apr 1, 1993
Sector: Health Care
Industry: Biotechnology
Website: amarincorp.com

Leadership

Amarin executives
Name	Title	Since	Age
Odysseas Kostas	—	—	50
Aaron Berg	—	2014	62
Peter Fishman	—	—	41
David Keenan	—	—	58
Stephen Ketchum	—	—	60
Jonathan Provoost	—	—	55
Patrice Bonfiglio	—	—	41
Paul Cohen	—	—	50
Keith Horn	—	—	66
Oliver O'Connor	—	—	63
Louis Sterling	—	—	46
Diane Sullivan	—	—	63
Michael Torok	—	—	46

Revenue by product and region

Fiscal year ended Dec 31, 2025: $213.65M total revenue

By product

Licensing and royalty.$30.89M14.5%
Product Revenue, Net$2.70M1.3%

Similar companies

Companies in the same industry as Amarin

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.